当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2021-10-21 , DOI: 10.1056/nejmoa2036205
Sven M Francque 1 , Pierre Bedossa 1 , Vlad Ratziu 1 , Quentin M Anstee 1 , Elisabetta Bugianesi 1 , Arun J Sanyal 1 , Rohit Loomba 1 , Stephen A Harrison 1 , Rozalina Balabanska 1 , Lyudmila Mateva 1 , Nicolas Lanthier 1 , Naim Alkhouri 1 , Christophe Moreno 1 , Jörn M Schattenberg 1 , Diana Stefanova-Petrova 1 , Luisa Vonghia 1 , Régine Rouzier 1 , Maeva Guillaume 1 , Alexander Hodge 1 , Manuel Romero-Gómez 1 , Philippe Huot-Marchand 1 , Martine Baudin 1 , Marie-Paule Richard 1 , Jean-Louis Abitbol 1 , Pierre Broqua 1 , Jean-Louis Junien 1 , Manal F Abdelmalek 1 ,
Affiliation  

New England Journal of Medicine, Volume 385, Issue 17, Page 1547-1558, October 2021.


中文翻译:

Pan-PPAR 激动剂 Lanifibranor 在 NASH 中的随机对照试验

新英格兰医学杂志,第 385 卷,第 17 期,第 1547-1558 页,2021 年 10 月。
更新日期:2021-10-21
down
wechat
bug